{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:12Z","timestamp":1792785852088,"version":"4.5.0"},"reference-count":126,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ministry of Culture and Science Northrine-Westfalia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1093\/ckj\/sfy103","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T23:47:27Z","timestamp":1536796047000},"page":"i2-i13","source":"Crossref","is-referenced-by-count":42,"title":["Management of autosomal-dominant polycystic kidney disease\u2014state-of-the-art"],"prefix":"10.1093","volume":"11","author":[{"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Department II of Internal Medicine, Center for Molecular Medicine Cologne, University of Cologne, Germany"},{"name":"Center for Rare and Hereditary Kidney Diseases, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Benzing","sequence":"additional","affiliation":[{"name":"Department II of Internal Medicine, Center for Molecular Medicine Cologne, University of Cologne, Germany"},{"name":"Center for Rare and Hereditary Kidney Diseases, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/43913","article-title":"A polycystic kidney-disease gene homologue required for male mating behaviour in C. elegans","volume":"401","author":"Barr","year":"1999","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B2","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1097\/01.ASN.0000029587.47950.25","article-title":"The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia","volume":"13","author":"Yoder","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nrneph.2014.173","article-title":"An approach to cystic kidney diseases: the clinician\u2019s view","volume":"10","author":"Kurschat","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fped.2018.00065","article-title":"Cystic kidney diseases from the adult nephrologist\u2019s point of view","volume":"6","author":"M\u00fcller","year":"2018","journal-title":"Front Pediatr"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1681\/ASN.2015050544","article-title":"Hepatocyte nuclear factor 1\u03b2-associated kidney disease: more than renal cysts and diabetes","volume":"27","author":"Verhave","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ki.2015.28","article-title":"Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management\u2013A KDIGO consensus report","volume":"88","author":"Eckardt","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ndt\/gft437","article-title":"Extra-renal manifestations of ADPKD: considerations for routine screening and management","volume":"29","author":"Luciano","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B9","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1681\/ASN.2017010084","article-title":"Biliary tract and liver complications in polycystic kidney disease","volume":"28","author":"Judge","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B12","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1681\/ASN.2014030297","article-title":"Imaging-based diagnosis of autosomal dominant polycystic kidney disease","volume":"26","author":"Pei","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B13","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B14","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B15","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12881-017-0416-5","article-title":"Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer","volume":"18","author":"Bartram","year":"2017","journal-title":"BMC Med Genet"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B17","first-page":"1857","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial","volume":"32","author":"Irazabal","year":"2017","journal-title":"Transplant"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B18","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B19","doi-asserted-by":"crossref","first-page":"42515","DOI":"10.18632\/oncotarget.6452","article-title":"Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials","volume":"6","author":"Xue","year":"2015","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B20","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease","volume":"323","author":"Chapman","year":"1990","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1573402114666180322110209","article-title":"Determinants of progression in early autosomal dominant polycystic kidney disease: is it blood pressure or renin-angiotensin-aldosterone-system blockade?","volume":"14","author":"Brosnahan","year":"2018","journal-title":"Curr Hypertens Rev"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B22","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1681\/ASN.2006060603","article-title":"Water for ADPKD? Probably, yes","volume":"17","author":"Torres","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B23","doi-asserted-by":"crossref","first-page":"e018794","DOI":"10.1136\/bmjopen-2017-018794","article-title":"Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)","volume":"8","author":"Wong","year":"2018","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.04180609","article-title":"A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease","volume":"5","author":"Barash","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2215\/CJN.03950510","article-title":"Water prescription in autosomal dominant polycystic kidney disease: a pilot study","volume":"6","author":"Wang","year":"2011","journal-title":"Clin J Am Soc Nephrology"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B26","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1056\/NEJMoa0907355","article-title":"Projected effect of dietary salt reductions on future cardiovascular disease","volume":"362","author":"Bibbins-Domingo","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B28","doi-asserted-by":"crossref","DOI":"10.1007\/s40620-018-0470-x","article-title":"Nutritional therapy in autosomal dominant polycystic kidney disease","author":"Di Iorio","year":"2018","journal-title":"J Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ki.1992.358","article-title":"Effects of dietary protein restriction and oil type on the early progression of murine polycystic kidney disease","volume":"42","author":"Aukema","year":"1992","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B30","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1681\/ASN.V561355","article-title":"Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease","volume":"5","author":"Tomobe","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B31","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.V5122037","article-title":"Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group","volume":"5","author":"Klahr","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","article-title":"A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group","volume":"336","author":"Appel","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B34","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B35","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B36","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","author":"Kipp","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B38","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","article-title":"Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model","volume":"300","author":"Leonhard","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B39","doi-asserted-by":"crossref","first-page":"e0181087","DOI":"10.1371\/journal.pone.0181087","article-title":"Generation and phenotypic characterization of Pde1a mutant mice","volume":"12","author":"Wang","year":"2017","journal-title":"PloS One"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B40","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1097\/01.ASN.0000025282.48298.7B","article-title":"The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease","volume":"13","author":"Belibi","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B41","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1053\/ajkd.2001.28614","article-title":"Chronic caffeine consumption exacerbates hypertension in rats with polycystic kidney disease","volume":"38","author":"Tanner","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40620-017-0396-8","article-title":"Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study","volume":"31","author":"Girardat-Rotar","year":"2018","journal-title":"J Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B43","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1590\/S0100-879X2012007500120","article-title":"Caffeine intake by patients with autosomal dominant polycystic kidney disease","volume":"45","author":"Vendramini","year":"2012","journal-title":"Braz J Med Biol Res"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B44","doi-asserted-by":"crossref","first-page":"j5024","DOI":"10.1136\/bmj.j5024","article-title":"Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes","volume":"359","author":"Poole","year":"2017","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B45","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/S0140-6736(07)60782-X","article-title":"How to prevent 100 million deaths from tobacco","volume":"369","author":"Frieden","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ndt\/gfw452","article-title":"Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies","volume":"32","author":"Xia","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B47","first-page":"1","article-title":"Effects of smoking on ADPKD: frequency of vascular events and concentrations of soluble CD40 ligand","volume":"3","author":"Brody","year":"2015","journal-title":"Gen Med Open Access"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B48","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1523-1755.1998.00067.x","article-title":"Smoking as a risk factor for end-stage renal failure in men with primary renal disease","volume":"54","author":"Orth","year":"1998","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10157-012-0706-3","article-title":"Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience","volume":"17","author":"Ozkok","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B50","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1210\/jcem-51-1-170","article-title":"Evidence in man that cigarette smoking induces vasopressin release via an airway-specific mechanism","volume":"51","author":"Rowe","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B51","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0000000000004419","article-title":"Association of intracranial aneurysm rupture with smoking duration, intensity, and cessation","volume":"89","author":"Can","year":"2017","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamainternmed.2016.8014","article-title":"Association of \u201cweekend warrior\u201d and other leisure time physical activity patterns with risks for all-cause, cardiovascular disease, and cancer mortality","volume":"177","author":"O\u2019Donovan","year":"2017","journal-title":"JAMA Intern Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B53","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamainternmed.2015.0533","article-title":"Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship","volume":"175","author":"Arem","year":"2015","journal-title":"JAMA Intern Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B54","doi-asserted-by":"crossref","first-page":"e1001335","DOI":"10.1371\/journal.pmed.1001335","article-title":"Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis","volume":"9","author":"Moore","year":"2012","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B55","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1001\/jamainternmed.2016.1548","article-title":"Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults","volume":"176","author":"Moore","year":"2016","journal-title":"JAMA Intern Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B56","author":"WHO","year":"2018"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B57","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrneph.2016.187","article-title":"Physical inactivity: a risk factor and target for intervention in renal care","volume":"13","author":"Zelle","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B58","doi-asserted-by":"crossref","first-page":"7191826","DOI":"10.1155\/2017\/7191826","article-title":"Physical exercise and patients with chronic renal failure: a meta-analysis","volume":"2017","author":"Qiu","year":"2017","journal-title":"Biomed Res Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11906-013-0386-8","article-title":"Physical activity and the prevention of hypertension","volume":"15","author":"Diaz","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"Van Gastel","year":"2017","journal-title":"Ann Nutr Metab"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B61","first-page":"1282","article-title":"Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease","volume":"26","author":"Sherstha","year":"1997","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B62","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.semnephrol.2015.10.015","article-title":"KHA-CARI autosomal dominant polycystic kidney disease guideline: management of polycystic liver disease","volume":"35","author":"Savige","year":"2015","journal-title":"Semin Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B63","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.3748\/wjg.v12.i22.3537","article-title":"Estrogens and the pathophysiology of the biliary tree","volume":"12","author":"Alvaro","year":"2006","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B64","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2215\/CJN.01970309","article-title":"Physical activity and mortality in chronic kidney disease (NHANES III)","volume":"4","author":"Beddhu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B65","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B66","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B67","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1681\/ASN.V34984","article-title":"Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro","volume":"3","author":"Ye","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B68","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B69","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B70","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B71","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ki.1996.445","article-title":"Chloride and fluid secretion by cultured human polycystic kidney cells","volume":"50","author":"Wallace","year":"1996","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B72","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","article-title":"Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease","volume":"30","author":"Yamaguchi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B73","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2013010077","article-title":"Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease","volume":"25","author":"Rees","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B74","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/mol.108.050567","article-title":"Thiophenecarboxylate suppressor of cyclic nucleotides discovered in a small-molecule screen blocks toxin-induced intestinal fluid secretion","volume":"75","author":"Tradtrantip","year":"2009","journal-title":"Mol Pharmacol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1523-1755.1998.00990.x","article-title":"Regulation of cAMP production in initial and terminal inner medullary collecting ducts","volume":"54","author":"Yasuda","year":"1998","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B76","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B77","doi-asserted-by":"crossref","first-page":"F931","DOI":"10.1152\/ajprenal.00604.2013","article-title":"The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors","volume":"306","author":"Juul","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B78","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1056\/NEJM198804073181403","article-title":"Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus","volume":"318","author":"Bichet","year":"1988","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B79","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<309::AID-DVG14>3.0.CO;2-5","article-title":"Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease","volume":"24","author":"Gattone","year":"1999","journal-title":"Dev Genet"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B80","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B81","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B82","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B83","doi-asserted-by":"crossref","first-page":"2054358117693355","DOI":"10.1177\/2054358117693355","article-title":"Total kidney volume as a biomarker of disease progression in autosomal dominant polycystic kidney disease","volume":"4","author":"Tangri","year":"2017","journal-title":"Can J Kidney Health Dis"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B84","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneph.2016.135","article-title":"The importance of total kidney volume in evaluating progression of polycystic kidney disease","volume":"12","author":"Grantham","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B85","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B86","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B87","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B88","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B89","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B90","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/ndt\/gfx079","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4: 4 trial","volume":"32","author":"Torres","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B91","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B92","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B93","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3: 4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B94","author":"The German ADPKD Tolvaptan Treatment Registry"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B95","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Safety"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B96","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B97","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ckj\/sfx071","article-title":"Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan","volume":"11","author":"M\u00fcller","year":"2018","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B98","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.03960318","article-title":"Recent advances in the management of autosomal dominant polycystic kidney disease","author":"Chebib","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B99","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0014-5793(86)81180-2","article-title":"Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells","volume":"198","author":"Friedlander","year":"1986","journal-title":"FEBS Lett"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2019, 5\u2019-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B102","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B103","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B104","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40264-016-0486-x","article-title":"Hepatic cyst infection during use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the randomized open-label multicenter DIPAK-1 study","volume":"40","author":"Lantinga","year":"2017","journal-title":"Drug Safety"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B105","doi-asserted-by":"crossref","first-page":"i637","DOI":"10.1093\/ndt\/gfy146.LB04","article-title":"LB04 renoprotective efficacy and safety of the somatostatin analogue lanreotide in later stage ADPKD","volume":"33","author":"Gansevoort","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B106","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","article-title":"Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease","volume":"90","author":"Hogan","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B107","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2013.04.055","article-title":"Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data","volume":"145","author":"Gevers","year":"2013","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B108","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/apt.13301","article-title":"Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials","volume":"42","author":"Neijenhuis","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B109","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.kint.2017.12.026","article-title":"Drug repurposing in kidney disease","volume":"94","author":"Panchapakesan","year":"2018","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B110","doi-asserted-by":"crossref","first-page":"F854","DOI":"10.1152\/ajprenal.00059.2007","article-title":"Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model","volume":"293","author":"Zafar","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B111","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0272-6386(95)90497-2","article-title":"Effect of lovastatin on the development of polycystic kidney disease in the Han: SPRD rat","volume":"26","author":"Gile","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B112","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B113","first-page":"109","article-title":"Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials","volume":"13","author":"Brosnahan","year":"2017","journal-title":"Curr Hypertens Rev"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B114","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B115","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","article-title":"Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B116","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000488807","article-title":"A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease","volume":"47","author":"Seliger","year":"2018","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B117","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01360210","article-title":"Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases","volume":"5","author":"Torres","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B118","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B119","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B120","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B121","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B122","doi-asserted-by":"crossref","first-page":"F395","DOI":"10.1152\/ajprenal.00057.2018","article-title":"Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease","volume":"315","author":"Kipp","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B123","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B124","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm.2171","article-title":"Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models","volume":"16","author":"Natoli","year":"2010","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B125","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1172\/JCI64401","article-title":"Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease","volume":"123","author":"Zhou","year":"2013","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019012510535530600_sfy103-B126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/11\/suppl_1\/i2\/27039974\/sfy103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T22:40:24Z","timestamp":1693867224000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/11\/suppl_1\/i2\/5232640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":126,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2018,12,17]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfy103","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,12,1]]}}}